An integrated cost-performance model of research and development evaluation

Geisler, Eliezer

doi:10.1016/0305-0483(95)00006-a

Cited by 60 publications

(29 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Geisler used publications and patents in his analysis of two national laboratories (Geisler, 1995). Thus, there is ample precedent for using this indicator to evaluate ALM R&D projects.…”

Section: National Research Council Indicatorsmentioning

confidence: 99%

Evaluation of the Benefits Attributable to Automotive Lighweight Materials Program Research and Development Projects

Das

Peretz

Tonn³

2002

View full text Add to dashboard Cite

“…Geisler used publications and patents in his analysis of two national laboratories (Geisler, 1995). Thus, there is ample precedent for using this indicator to evaluate ALM R&D projects.…”

Section: National Research Council Indicatorsmentioning

confidence: 99%

Evaluation of the Benefits Attributable to Automotive Lighweight Materials Program Research and Development Projects

Das

Peretz

Tonn³

2002

View full text Add to dashboard Cite

“…In considering the input and output of R&D, we cannot immediately specify what to be as the output, compared with R&D investment as the input. Geisler (1995) and Brown and Svenson (1998) list published articles, patents, new products, etc. as the output.…”

Section: Introductionmentioning

confidence: 99%

Measuring the change in R&D efficiency of the Japanese pharmaceutical industry

Hashimoto¹,

Haneda²

2008

Research Policy

172

View full text Add to dashboard Cite

This paper presents a DEA (Data Envelopment Analysis)/ Malmquist index methodology for measuring the R&D efficiency change of the Japanese pharmaceutical industry. Letting each of ten firms each year be a separate DMU (Decision-Making Unit) and employing one input and three outputs in the DEA, and using the cumulative frontier shift component on average proposed in the Malmquist index analysis, we quite obviously show the industry-wide R&D efficiency change for the period 1982-2001. The results empirically reveal that the R&D efficiency of the Japanese industry, which has seemed elusive, has surely gotten worse almost monotonically for these twenty years at least as to the pharmaceutical one.

show abstract

“…Various mechanisms exist to monitor and encourage these dissemination and transformation efforts. One method is to first identify representative organizations and institutions at each stage and then to monitor transformation activities and the number of outputs and inputs at each stage [Geisler, 1995[Geisler, , 1998]. …”

Section: Framework For Tracking Dissemination Effortsmentioning

confidence: 99%